Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252499 · ClinicalTrials.gov registry record · NA
Insulin Resistance in Non-alcoholic Fatty Liver Disease
A NA study, sponsored by US Department of Veterans Affairs.
- Terminated
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT00252499 is a NA study that was terminated before completion, run by US Department of Veterans Affairs. The registered enrollment target is 13 participants.
The verdict
NCT00252499, a NA study, was terminated before completion, sponsored by US Department of Veterans Affairs.
- TERMINATED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether nonalcoholic fatty liver disease (NAFLD) is associated with altered peripheral and hepatic insulin sensitivity and to investigate potential mechanisms underlying insulin resistance in NAFLD by determining associations between hepatic and peripheral insulin sensitivity, hepatic steatosis, dyslipidemia, inflammatory cytokines, glucose metabolism, beta-cell function and body fat distribution.
Interventions
- DRUG rosiglitazone
- DRUG fenofibrate
- DRUG placebo for rosiglitazone
- DRUG placebo for fenofibrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2005-10 |
| Est. Completion | 2010-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00252499
The ClinicalTrials.gov registry entry for NCT00252499 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which rosiglitazone is the first listed.
NCT00252499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00252499 about?
NCT00252499 is a clinical study titled "Insulin Resistance in Non-alcoholic Fatty Liver Disease". The purpose of this study is to determine whether nonalcoholic fatty liver disease (NAFLD) is associated with altered peripheral and hepatic insulin sensitivity and to investigate potential mechanisms underlying insulin resistance in NAFLD by determining associations between hepatic and peripheral i...
What is the current status of trial NCT00252499?
This trial is currently terminated. It is a NA study. The enrollment target is 13 participants. The study started on 2005-10. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00252499?
The interventions under investigation include: rosiglitazone (DRUG), fenofibrate (DRUG), placebo for rosiglitazone (DRUG), placebo for fenofibrate (DRUG).
Who is sponsoring clinical trial NCT00252499?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.